FDA Moves On CBD, Signaling A New Phase For The Market

The agency has sent a CBD compliance and enforcement policy to the White House for review, a quiet but important step that could bring more structure to one of the most uncertain corners of the cannabis economy.

The FDA has made a meaningful move on CBD.

On March 13, 2026, the agency submitted a notice titled Cannabidiol (CBD) Products Compliance and Enforcement Policy to the White House Office of Information and Regulatory Affairs for review. The filing appears on Reginfo as a pending Executive Order 12866 review and is classified as a notice rather than a proposed rule or final rule.

Even without the full text of the policy, the signal is clear: after years of uncertainty, the federal government appears to be taking a more defined approach to CBD compliance and enforcement.

For the industry, that matters.

CBD has spent years in regulatory limbo. The market grew quickly, consumer demand remained strong and operators built businesses in a category where federal policy never fully caught up with commercial reality. The result was a marketplace full of opportunity, but also one marked by inconsistent standards, uneven enforcement and ongoing uncertainty for serious operators.

This filing could be an early step toward changing that.

Back in 2023, the FDA said existing frameworks for foods and dietary supplements were not appropriate for cannabidiol and that a new regulatory pathway would be needed. This latest move suggests the agency may now be working toward a more practical compliance posture while broader cannabis and hemp policy continues to evolve.

That could have real implications across the supply chain. A clearer federal framework may help strengthen consumer trust, improve quality expectations and create more predictable conditions for operators that have invested in compliance, manufacturing discipline and long-term brand building. It could also help distinguish serious businesses from bad actors who have benefited from the market’s lack of clarity.

Anthony Varrell, writing in Cannabis Confidential, described the filing as “the first step toward structured federal oversight of the sprawling CBD marketplace.” That may prove to be the right way to frame it. While the policy itself has not yet been released, the filing suggests the FDA is no longer content to remain on the sidelines.

The timing is also notable. Federal cannabis policy has become more active in recent months, with continued attention on research, rescheduling and the future of hemp-derived products. Against that backdrop, a more defined CBD compliance policy would fit into a broader trend toward a more structured federal posture.

For now, the market still does not have the details. The policy text is not public, and it remains unclear how narrowly or broadly the FDA intends to act. But for operators, investors and stakeholders across the hemp and cannabis economy, this filing is worth watching closely.

After years of waiting, CBD may finally be entering its next regulatory chapter.

Photo: The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons